Osteocyte control of bone formation via sclerostin, a novel BMP antagonist.

@article{Winkler2003OsteocyteCO,
  title={Osteocyte control of bone formation via sclerostin, a novel BMP antagonist.},
  author={David G. Winkler and May S Kung Sutherland and James C. Geoghegan and Changpu Yu and Trenton Hayes and John E Skonier and Diana Shpektor and Mechtild Jonas and Brian R Kovacevich and Karen Staehling-Hampton and Mark Appleby and Mary E. Brunkow and John A Latham},
  journal={The EMBO journal},
  year={2003},
  volume={22 23},
  pages={6267-76}
}
There is an unmet medical need for anabolic treatments to restore lost bone. Human genetic bone disorders provide insight into bone regulatory processes. Sclerosteosis is a disease typified by high bone mass due to the loss of SOST expression. Sclerostin, the SOST gene protein product, competed with the type I and type II bone morphogenetic protein (BMP) receptors for binding to BMPs, decreased BMP signaling and suppressed mineralization of osteoblastic cells. SOST expression was detected in… CONTINUE READING
Highly Influential
This paper has highly influenced 26 other papers. REVIEW HIGHLY INFLUENTIAL CITATIONS
Related Discussions
This paper has been referenced on Twitter 2 times. VIEW TWEETS

Citations

Publications citing this paper.
Showing 1-10 of 335 extracted citations

Bone morphogenetic proteins and their antagonists

Reviews in Endocrine and Metabolic Disorders • 2006
View 6 Excerpts
Highly Influenced

DNA Methylation in Osteoarthritis: Current Status and Therapeutic Implications

The open rheumatology journal • 2018
View 10 Excerpts
Highly Influenced

Sclerostin and Adipose Tissue

Current Molecular Biology Reports • 2017
View 4 Excerpts
Highly Influenced

Similar Papers

Loading similar papers…